An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Phase 2 Withdrawn Jazz Pharmaceuticals Food and Drug Administration (FDA) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.

Timeline

Start: 2014-10
Primary completion: 2015-11
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brincidofovir	Other / unclassified	100 mg	—

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Summary

Timeline

Drugs

Indications